Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

3 Cannabis Developments to Know: GW Pharma, Canopy Growth, Aurora Cannabis

Mar 7, 2017 • 11:51 AM EST
4 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

The cannabis sector is in the early innings of a multi-decade growth cycle that should create more millionaires than the tech boom.

Today, want to provide an update on some of the corporate initiatives at some of the leading global cannabis companies.

Leading Biotech Company Announces New CFO

GW Pharmaceuticals plc (GWPH) announced the appointment of Scott Giacobello as Chief Financial Officer. Giacobello will be based out of Carlsbad, California. The previous CFO (since 2012), Adam George is the Managing Director – UK, a newly-created executive role with broad leadership responsibilities for UK operations.

Giacobello served as Chief Financial Officer for Chase Pharmaceuticals Corporation until Allergan acquired it. Chase was a clinical stage biopharmaceutical company focused on the development and commercialization of improved treatments for neurodegenerative disorders. From 2008 through 2015, Giacobello held senior level finance positions at Allergan, most recently serving as Vice President of Finance for Global Research & Development.

Under his new position, George will make sure the company’s UK operations achieve its goals, which include pipeline development, manufacturing scale-up, and European commercialization. He will continue as GW’s Secretary and will provide Giacobello with full support through the CFO transition.

We are favorable on this announcement and see significant long-term upside to current levels. GWPH is one of the best long-term cannabis investment opportunities and if the market continues to see weakness, a great buying opportunity will be created for potential GWPH investors.

Leading Canadian Cannabis Retailer Faces Legal Headwinds

Canopy Growth Corp (WEED.TO) (TWMJF) is facing legal headwinds after a law firm issued a lawsuit on behalf of a patient of Mettrum. The claim is for millions of dollars and states that Mettrum has failed to pay refunds to its customers for all the marijuana products in question.

Although these issues are mostly priced into shares of Canopy, we would not be surprised if WEED.TO and TWMJF traded lower off this news. The company has seen weakness over the last week and WEED.TO is down 5% during that time.

Aurora Announces New Acquisition

Aurora Cannabis’ (ACB.V: TSX Venture) (ACBFF) acquisition of Peloton Pharmaceuticals was approved. Peloton is a late-stage ACMPR-applicant and they are building a 40,000 square-foot cannabis production facility in Quebec. Aurora paid $7,000,000 of cash and stock.

In 2014, the facility received a “ready to build” letter from Health Canada. The company estimates that production is 80% complete and thinks it will be reading for a Health Canada inspection for a production license by the summer of 2017.

Although we are favorable on Aurora’s management team, its current expansion, its improving fundamentals and its balance sheet; the company’s current valuation keeps us on the sidelines.

While we have been very favorable on the company’s inorganic growth initiatives (acquisitions), these have increased the value of the company on a diluted basis. We believe a lot of the expected growth is already priced into Aurora and we plan to re-enter on weakness.


Important Investor Disclosures

Disclosure.  Compensated Affiliate.  This report was authored by and is property of StoneBridge Partners LLC.  All information and data relied upon in drafting this report is publicly available. The author believes and considers its sources to be reliable, but does not guarantee the accuracy or completeness of any information contained in this report.  Any and all information, data, analyses and opinions are provided for informational purposes only and is not intended, in any manner, as investment advice.  Any projections or other information generated by StoneBridge Partners LLC regarding the likelihood of various investment outcomes are hypothetical in nature, do not reflect actual investment results, and are not guarantees of future results.  None of the material contained in this report is intended as a solution or offer to sell or purchase a specific stock or any other investment.  This report is not directed to, or intended for distribution or use by, any person or entity that is a citizen, resident or located in any municipality, state, country or other jurisdiction where the distribution, publication, availability, or use of this report is contrary to any governing law or regulation.  The securities discussed in this report may not be eligible for purchase and/or sale in certain jurisdictions or by particular individuals.  It is important that you check any and all governing laws and/or regulations that may be applicable in your jurisdiction.  Investing in securities of issuers organized outside of the United States, including ADRs, entail certain risks.  The securities of non-United States issuers may not be registered with, nor be subject to the reporting requirements of the United States Securities and Exchange Commission.  Please contact a Financial Advisor for professional adviceregarding any and all securities investments.  This report is intended for informational purposes only.  StoneBridge Partners LLC’s officers, directors, employees, affiliates, or subsidiaries may have positions in securities covered by StoneBridge Partners LLC.  StoneBridge Partners LLC receives compensation from the company and/or has a position in the securities mentioned in this report



Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.